West Pharmaceutical Services (WST) Receivables - Net (2009 - 2026)

West Pharmaceutical Services (WST) has reported Receivables - Net for 18 consecutive years, with $712.0 million the latest figure, recorded in Q2 2026.

• Quarterly Receivables - Net rose 22.25% year-over-year to $712.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $712.0 million (up 22.25% YoY) and the FY2025 annual result came in at $574.4 million, up 3.96% from the prior year.
• Receivables - Net climbed to $712.0 million in Q2 2026 per WST's latest filing, from $685.6 million in the prior quarter.
• Over the last five years, Receivables - Net for WST reached as high as $712.0 million in Q2 2026 and fell as low as $11.9 million in Q4 2025.
• A 5-year average of $518.9 million and a median of $524.2 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2025 — Receivables - Net plunged 97.85% — and 2026, when it gained 26.12%.
• Year by year, Receivables - Net stood at $507.4 million in 2022, then climbed by 0.91% to $512.0 million in 2023, then climbed by 7.91% to $552.5 million in 2024, then tumbled by 97.85% to $11.9 million in 2025, then jumped by 5883.19% to $712.0 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $712.0 million, $685.6 million, and $11.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.